Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With <i>KIT</i> Exon 9 Mutations

In this large international cohort study of resected GISTs with KIT exon 9 mutations, adjuvant imatinib was independently associated with delayed recurrence and improved survival. These findings support the use of adjuvant imatinib in mNIH high-risk GISTs with KIT exon 9 mutations and underscore the need for prospective studies to define optimal dosing and treatment duration.

Authors

Institutions

Publication Details

Journal
JAMA Oncology
Published
2026-02-26
DOI
https://doi.org/10.1001/jamaoncol.2026.0007
Primary Topic
Gastrointestinal Tumor Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations

Andrea Napolitano, Alessandro Mazzocca, Skye C. Mayo, Jozef Šufliarský et al.
JAMA Oncology
Gastrointestinal Tumor Research and Treatment
article

Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations

Andrea Napolitano, Alessandro Mazzocca, Skye C. Mayo, Jozef Šufliarský, Hans Gelderblom, Thomas L. Sutton, Valentina Fausti, Maria Abbondanza Pantaleo, Andrea Bordoni, Ingrid M.E. Desar, Chiara Braconi, Peter Reichardt, GLORIA MARQUINA, Sonja E. Steigen, S Bauer, Jason J. Luke, Giacomo Giulio Baldi, Johanna Falkenhorst, Trent Jt, Neeltje Steeghs, Arun Singh, Magnús K. Magnússon, Elise F. Nassif, Neeta Somaiah, Claudia Cirilli, Piotr Rutkowski, Toshiro Nishida, Kjetil Boye, Antonella Brunello, Mariella Spalato Ceruso, Ferdinando C. M. Cananzi, Peter Hohenberger, Alessandro Gronchi, Denisse Evans, Bruno Vincenzi, Winan J. van Houdt, Nadia Hindi, Antoine Italiano, Axel Le Cesne, Heikki Joensuu, Bengt Nilsson, Massimo Federico, Paolo G. Casali, Jon G. Jonasson, Elena Fumagalli, Javier Martin-Broto, Sara Rothschild
article en

Abstract

In this large international cohort study of resected GISTs with KIT exon 9 mutations, adjuvant imatinib was independently associated with delayed recurrence and improved survival. These findings support the use of adjuvant imatinib in mNIH high-risk GISTs with KIT exon 9 mutations and underscore the need for prospective studies to define optimal dosing and treatment duration.

JAMA Oncology
University of Modena and Reggio Emilia (IT), Reykjavík University (IS), Oslo University Hospital (NO), University Hospital of North Norway (NO), University of Helsinki (FI), Humanitas University (IT), The University of Texas MD Anderson Cancer Center (US), Radboud University Nijmegen (NL), University of California, Los Angeles (US), University of Iceland (IS), Oregon Health & Science University (US), Heidelberg University (DE), Leiden University Medical Center (NL), Helsinki University Hospital (FI), Sahlgrenska University Hospital (SE), Institut Gustave Roussy (FR), University Hospital Heidelberg (DE), Radboud University Medical Center (NL), The Netherlands Cancer Institute (NL), Hospital Clínico San Carlos (ES), Azienda Unita' Sanitaria Locale Di Modena (IT), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (ES), University of Miami Health System (US), Centre Léon Bérard (FR), National University Hospital of Iceland (IS), Istituto Oncologico Veneto (IT), Essen University Hospital (DE), Royal Marsden Hospital (GB), Instituto de Biomedicina de Sevilla (ES), Institut Bergonié (FR), Campus Bio Medico University Hospital (IT), VA Portland Health Care System (US), National Cancer Center Hospital East (JP), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), Candiolo Cancer Institute (IT), Istituto Cantonale di Patologia (CH), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Helios Hospital Berlin-Buch (DE), University Medical Centre Mannheim (DE), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Sylvester Comprehensive Cancer Center (US), IRCCS Humanitas Research Hospital (IT), Life Raft Group (US), Hospital of Prato (IT), Comenius University Bratislava (SK), University of Glasgow (GB), University of Bologna (IT)
Good health and well-being
Openalex Percentile: Top 41%
Gastrointestinal Tumor Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.